|
Comprehensive genomic profiling of metastatic cutaneous adnexal carcinomas to reveal multiple routes to targeted and immunotherapies. |
|
|
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; MSD; Novartis; Pfizer; Roche |
|
|
Employment - Foundation Medicine |
Stock and Other Ownership Interests - Foundation Medicine; Gilead Sciences |
|
|
Employment - Foundation Medicine |
Stock and Other Ownership Interests - Foundation Medicine |
|
|
Employment - Foundation Medicine |
Stock and Other Ownership Interests - Foundation Medicine |
|
|
Employment - Foundation Medicine |
Stock and Other Ownership Interests - Foundation Medicine |
|
|
Employment - Foundation Medicine |
|
|
Employment - Foundation Medicine |
Stock and Other Ownership Interests - Foundation Medicine |
|
|
Employment - Foundation Medicine |
|
|
No Relationships to Disclose |
|
|
Employment - Foundation Medicine; Foundation Medicine |
Stock and Other Ownership Interests - Agios; Blueprint Medicines; Exelixis |
Patents, Royalties, Other Intellectual Property - patents via FOundation Medicine; Patents via Seres Health on microbiome stuff in non neoplastic disease (I) |
|
|
Employment - Foundation Medicine |
Stock and Other Ownership Interests - Foundation Medicine |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - Foundation Medicine |
Leadership - Foundation Medicine |
Stock and Other Ownership Interests - Foundation Medicine |
Patents, Royalties, Other Intellectual Property - Receive periodic royalties related to T790M patent awarded to Memorial Sloan Kettering Cancer Center |
|
|
No Relationships to Disclose |
|
|
Employment - Foundation Medicine |
Leadership - Foundation Medicine |
Stock and Other Ownership Interests - Foundation Medicine |
Research Funding - Foundation Medicine |